Download PDF
CC BY 4.0 · Glob Med Genet 2020; 07(03): 087-091
DOI: 10.1055/s-0040-1722170
Original Article

Reduced Expression of GPX3 in Breast Cancer Patients in Correlation with Clinical Significance

Pensri Saelee
1   Division of Research, National Cancer Institute, Bangkok, Thailand
,
Tanett Pongtheerat
2   Unit of Biochemistry, Department of Medical Sciences, Faculty of Science, Rangsit University, Patumthani, Thailand
,
Thanet Sophonnithiprasert
2   Unit of Biochemistry, Department of Medical Sciences, Faculty of Science, Rangsit University, Patumthani, Thailand
› Author Affiliations Funding This work was supported by a grant from the Fiscal Budget of the Royal Thai Government.
› Further Information
   Permissions and Reprints

Abstract

Glutathione peroxidase 3 (GPX3) is the main antioxidant enzyme in plasma. Its biological roles are to protect cells from oxidative stress-induced damage. Several studies have been reported the association between GPX3 expression and its correlation with cancer carcinogenesis including breast cancer. The aim of this research was to investigate the GPX3 messenger ribonucleic acid (mRNA) expression in 82 breast tumors and paired normal breast tissues by SYBR green quantitative real-time reverse transcription-polymerase chain reaction and the association with clinicopathological data. Our results show that GPX3 reduced expression was found significantly associated with number of metastatic lymph nodes (odds ratio [OR] = 3.41, 95% confidence interval [CI] = 1.35–8.64, p = 0.01), no distant metastasis (OR = 5.52, 95% CI = 3.74–11.89, p = 0.04), and nonhormone usage breast cancer patients (OR = 0.19, 95% CI = 0.04–0.93, p = 0.04). This finding suggested that GPX3 plays a role in breast carcinogenesis, and might serve as a prognostic biomarker in breast cancer patients.

Keywords

breast cancer - GPX3 - antioxidant enzyme - gene expression - real-time reverse transcription-PCR


Publication History

Article published online:
26 December 2020

© 2020. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Baez-Duarte BG, Mendoza-Carrera F, García-Zapién A. et al; Multidisciplinary Research Group on Diabetes of the Instituto Mexicano del Seguro Social. Glutathione peroxidase 3 serum levels and GPX3 gene polymorphisms in subjects with metabolic syndrome. Arch Med Res 2014; 45 (05) 375-382
    CrossrefPubMedGoogle Scholar
  • 2 Liu K, Jin M, Xiao L, Liu H, Wei S. Distinct prognostic values of mRNA expression of glutathione peroxidases in non-small cell lung cancer. Cancer Manag Res 2018; 10 (10) 2997-3005
    CrossrefPubMedGoogle Scholar
  • 3 Min SY, Kim HS, Jung EJ, Jung EJ, Jee CD, Kim WH. Prognostic significance of glutathione peroxidase 1 (GPX1) down-regulation and correlation with aberrant promoter methylation in human gastric cancer. Anticancer Res 2012; 32 (08) 3169-3175
    Google Scholar
  • 4 Ambrosone CB. Oxidants and antioxidants in breast cancer. Antioxid Redox Signal 2000; 2 (04) 903-917
    CrossrefPubMedGoogle Scholar
  • 5 Cebrian A, Pharoah PD, Ahmed S. et al. Tagging single-nucleotide polymorphisms in antioxidant defense enzymes and susceptibility to breast cancer. Cancer Res 2006; 66 (02) 1225-1233
    CrossrefPubMedGoogle Scholar
  • 6 Peng DF, Hu TL, Schneider BG, Chen Z, Xu ZK, El-Rifai W. Silencing of glutathione peroxidase 3 through DNA hypermethylation is associated with lymph node metastasis in gastric carcinomas. PLoS One 2012; 7 (10) e46214
    CrossrefPubMedGoogle Scholar
  • 7 Zhang X, Zheng Z, Yingji S. et al. Downregulation of glutathione peroxidase 3 is associated with lymph node metastasis and prognosis in cervical cancer. Oncol Rep 2014; 31 (06) 2587-2592
    CrossrefPubMedGoogle Scholar
  • 8 Zhao H, Li J, Li X. et al. Silencing GPX3 expression promotes tumor metastasis in human thyroid cancer. Curr Protein Pept Sci 2015; 16 (04) 316-321
    CrossrefPubMedGoogle Scholar
  • 9 Yu YP, Yu G, Tseng G. et al. Glutathione peroxidase 3, deleted or methylated in prostate cancer, suppresses prostate cancer growth and metastasis. Cancer Res 2007; 67 (17) 8043-8050
    CrossrefPubMedGoogle Scholar
  • 10 Qi X, Ng KT, Lian QZ. et al. Clinical significance and therapeutic value of glutathione peroxidase 3 (GPx3) in hepatocellular carcinoma. Oncotarget 2014; 5 (22) 11103-11120
    CrossrefPubMedGoogle Scholar
  • 11 Mohamed MM, Sabet S, Peng DF, Nouh MA, El-Shinawi M, El-Rifai W. Promoter hypermethylation and suppression of glutathione peroxidase 3 are associated with inflammatory breast carcinogenesis. Oxid Med Cell Longev 2014; 2014: 787195
    CrossrefPubMedGoogle Scholar
  • 12 Lou W, Ding B, Wang S, Fu P. Overexpression of GPX3, a potential biomarker for diagnosis and prognosis of breast cancer, inhibits progression of breast cancer cells in vitro. Cancer Cell Int 2020; 20: 378
    CrossrefPubMedGoogle Scholar
  • 13 Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25 (04) 402-408
    CrossrefPubMedGoogle Scholar
  • 14 Jiao Y, Wang Y, Guo S. et al. Glutathione peroxidases as oncotargets. Oncotarget 2017; 8 (45) 80093-80102
    CrossrefPubMedGoogle Scholar
  • 15 Chen H, Zheng Z, Kim KY, Jin X, Roh MR, Jin Z. Hypermethylation and downregulation of glutathione peroxidase 3 are related to pathogenesis of melanoma. Oncol Rep 2016; 36 (05) 2737-2744
    CrossrefPubMedGoogle Scholar
  • 16 Yang ZL, Yang L, Zou Q. et al. Positive ALDH1A3 and negative GPX3 expressions are biomarkers for poor prognosis of gallbladder cancer. Dis Markers 2013; 35 (03) 163-172
    CrossrefPubMedGoogle Scholar